Key Insights

Highlights

Success Rate

76% trial completion

Published Results

22 trials with published results (11%)

Research Maturity

63 completed trials (30% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.6%

20 terminated out of 208 trials

Success Rate

75.9%

-10.6% vs benchmark

Late-Stage Pipeline

10%

20 trials in Phase 3/4

Results Transparency

35%

22 of 63 completed with results

Key Signals

22 with results76% success20 terminated

Data Visualizations

Phase Distribution

165Total
Not Applicable (21)
Early P 1 (5)
P 1 (41)
P 2 (78)
P 3 (16)
P 4 (4)

Trial Status

Completed63
Recruiting53
Unknown31
Terminated20
Active Not Recruiting16
Not Yet Recruiting15

Trial Success Rate

75.9%

Benchmark: 86.5%

Based on 63 completed trials

Clinical Trials (208)

Showing 20 of 20 trials
NCT05611034Phase 1Recruiting

In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

NCT06589830Phase 2RecruitingPrimary

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

NCT07550088Phase 2Not Yet RecruitingPrimary

BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

NCT03038568Active Not RecruitingPrimary

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

NCT06300463Phase 2RecruitingPrimary

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

NCT06634875Phase 2RecruitingPrimary

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

NCT05200442Phase 1Recruiting

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

NCT07486492Early Phase 1Not Yet RecruitingPrimary

Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer

NCT07172282Early Phase 1RecruitingPrimary

INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases

NCT07462650Phase 1RecruitingPrimary

Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer

NCT07193862Early Phase 1RecruitingPrimary

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

NCT06625515Phase 1Terminated

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

NCT03388190Phase 2CompletedPrimary

METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin

NCT07405736Phase 2Not Yet RecruitingPrimary

Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer

NCT05129787Not ApplicableActive Not RecruitingPrimary

Ablation vs Resection of Colorectal Cancer Liver Metastases

NCT06698146Recruiting

Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection

NCT07201519Phase 2RecruitingPrimary

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

NCT05665322Not ApplicableTerminatedPrimary

Evaluation of the Efficacy of Two Guidance Techniques (Standard Injected CT vs Porto-scanner With Angio-CT) for Thermoablation Treatment of Colorectal Cancer Liver Metastases

NCT05759728Phase 1RecruitingPrimary

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

NCT07328087Early Phase 1RecruitingPrimary

COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

Scroll to load more

Research Network

Activity Timeline